Future studies are needed to determine if enhanced expression of SOX17 or inhibition of its downstream targets such as RUNX1, HGF/c-Met, or E2F1 can reverse PAH associated with the rare or common variants of SOX17 mutations or in patients with PAH that are not associated with impaired SOX17 expression. Here, RUNX1 is linked to pulmonary arterial hypertension.